Biomarkers for Diagnosis and Prognosis of Cervical Cancer
Section: For Industry
Categories: "Diagnostics"
Reference #: 2003-025
OTC Contact: Ruchika Nijhara Ph.D. (Directory Information | Send a Message)
Description
Researchers at Georgetown University have identified a novel panel of biomarkers that could be used in the diagnosis, prognosis and treatment of cervical cancer or cervical dysplasia. The present invention relates to such methods by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length.
Applications
- Biomarkers can be used to classify the grade of cervical lesion for diagnostic and prognostic purposes.
- Use of gene-silencing to knock-down expression of the biomarkers
- Use panel for the screening of therapeutic agents that target one or more of the biomarkers
Advantages
- Noninvasive procedures
- Suitable for large scale screening of patients
- More accurate than conventional cytological screening
- Possible to select the treatment most appropriate for that patient by predicting the final diagnostic group of a patient by classifying the grade of a cervical lesion.
Stage of Development
In-vitro studies completed.Relevant Publications
Schlegel et al; “Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression”. Cancer Res. 2005 Jul 15;65(14):6199-206.
Schlegel et al;“IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis”. J Virol. 2004 Jun;78(11):5720-7.
Schlegel et al; “Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.” Am J Pathol. 2002 Aug;161(2):603-10.
Schlegel et al; “Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity”. Am J Pathol. 2002 Apr;160(4):1251-7.
Schlegel et al; “Simian virus 40 small tumor antigen activates AKT and telomerase and induces anchorage-independent growth of human epithelial cells”. J Virol. 2002 Nov;76(21):10685-91.
INVENTOR: Richard Schlegel
Patent Status
US Patent Application # 10/565,021 entitled, “Diagnosis and Treatment of Cervical Cancer” filed on January 17, 2006.
